Raymond James Upgrades Oncolytics Biotech (TSE:ONC) to “Moderate Buy”

Oncolytics Biotech (TSE:ONC) was upgraded by analysts at Raymond James to a “moderate buy” rating in a report issued on Thursday,Zacks.com reports. Raymond James also issued estimates for Oncolytics Biotech’s Q4 2024 earnings at ($0.12) EPS, FY2024 earnings at ($0.44) EPS, Q1 2025 earnings at ($0.12) EPS and FY2025 earnings at ($0.47) EPS.

Oncolytics Biotech Trading Down 2.1 %

Oncolytics Biotech stock opened at C$1.38 on Thursday. The company has a debt-to-equity ratio of 6.09, a quick ratio of 8.86 and a current ratio of 4.99. The business’s 50-day simple moving average is C$1.50 and its 200-day simple moving average is C$1.45. The firm has a market capitalization of C$106.07 million, a PE ratio of -3.63 and a beta of 1.35. Oncolytics Biotech has a 52 week low of C$1.15 and a 52 week high of C$2.32.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.